Two clinical trials testing the antibody Zynlonta (loncastuximab tesirine) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.
Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186.
Humana Inc. and Evolent Health Inc. announced an expansion of their strategic medical oncology partnership to modernize and streamline prior authorization processes to include radiation and surgical oncology services.
Kenneth C. Griffin, founder and CEO of Citadel and founder of Griffin Catalyst, gifted $50 million to Sylvester Comprehensive Cancer Center to help fund a 12-story, 244,000-square-foot cancer research building.